ACP
AMLX icon

Acuta Capital Partners’s Amylyx Pharmaceuticals AMLX Stock Holding History

Acuta Capital Partners’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.02M Buy
168,115
+17,048
+11% +$264K 2.1% 18
2026
Q1 		$2.1M Sell
151,067
-182,191
-55% -$2.56M 1.48% 17
2025
Q4 		$4.03M Hold
333,258
– – 2.73% 12
2025
Q3 		$4.53M Buy
+333,258
New +$3.14M 4.68% 8

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Acuta Capital Partners's AMLX Position: Q2 2026 in Review

Acuta Capital Partners increased its Amylyx Pharmaceuticals (AMLX) stake by 11% in Q2 2026, buying an estimated $264K and bringing the position to 168,115 shares worth $3.02M. The position accounts for 2.1% of the portfolio, ranked #18.

Acuta Capital Partners first reported a position in AMLX in Q3 2025 and has held it in 4 quarters since. The position peaked at $4.53M in Q3 2025. 206 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • Acuta Capital Partners held 168,115 shares of Amylyx Pharmaceuticals worth $3.02M as of Q2 2026.
  • Acuta Capital Partners bought 17,048 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $264K.
  • Amylyx Pharmaceuticals made up 2.1% of Acuta Capital Partners's portfolio in Q2 2026, its #18 holding.
  • Acuta Capital Partners first reported a position in Amylyx Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Acuta Capital Partners's Amylyx Pharmaceuticals position peaked at $4.53M in Q3 2025.
  • 206 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Acuta Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.